ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

A. Reinacher-Schick; D. Arnold; F. Lordick; M. Möhler; M. P. Lutz; T. Seufferlein

doi:10.1055/s-2006-927142

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml

Download PDF

Z Gastroenterol 2006; 44(10): 1065-1072
DOI: 10.1055/s-2006-927142

Übersicht

ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

ASCO Update 2006 - Highlights of the 42. Meeting of the American Society of Clinical Oncology/ASCO 2006A. Reinacher-Schick¹ , D. Arnold² , F. Lordick³ , M. Möhler⁴ , M. P. Lutz⁵ , T. Seufferlein⁶ [*] ¹

¹Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
²Klinik für Innere Medizin IV, Universität Halle
³III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
⁴I. Medizinische Klinik und Poliklinik, Universität Mainz
⁵Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
⁶Klinik für Innere Medizin I, Universitätsklinikum Ulm

Further Information

Publication History

Publication Date:
25 October 2006 (online)

Also available at

Permissions and Reprints

Zusammenfassung

Kaum ein Gebiet der Gastroenterologie hat sich in den letzten Jahren so schnell entwickelt wie die Therapie gastrointestinaler Tumoren, nicht zuletzt durch den Einsatz von Targeted Therapies. Wir möchten Ihnen in der folgenden Übersicht wie bereits im vergangenen Jahr [22] die wichtigsten neuen klinischen Studien zu Ösophagus-, Magen-, kolorektalen, Pankreas-, Leber- und Gallenwegskarzinomen vorstellen und bewerten, die auf dem diesjährigen Meeting der American Society of Clinical Oncology präsentiert wurden.

Abstract

Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review will give an overview on the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - Gallenwegskarzinom - Targeted Therapies - klinische Studien

Key words

esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - targeted therapies - clinical trials

Literatur
(Angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

1 Al-Batran S. et al . A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). JCO. 2006; 24 (18S) LBA4016

Reference Link Ris
PubMed Search in Google Scholar
2 Arnold D. et al . , Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). JCO. 2006; 24 (18S) A3574

Reference Link Ris
PubMed Search in Google Scholar
3 Bosset J F. et al . Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22 921 trial. JCO. 2005; 23 A3505

Reference Link Ris
PubMed Search in Google Scholar
4 Carr B I. et al . Gemcitabine hepatic arterial chemoembolization (TACE) in the treatment of unresectable HCC. JCO. 2006; 24 (18S) A4141

Reference Link Ris
PubMed Search in Google Scholar
5 Cassidy J. et al . Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). JCO. 2006; 24 (18S) A3507

Reference Link Ris
PubMed Search in Google Scholar
6 Chauffert C. et al . Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. JCO. 2006; 24 (18S) A4008

Reference Link Ris
PubMed Search in Google Scholar
7 Chung K Y. et al . Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. JCO. 2006; 24 (18S) A3560

Reference Link Ris
PubMed Search in Google Scholar
8 Cohn A. et al . Single-agent pemetrexed in patients with advanced and metastatic hepatoma. JCO. 2006; 24 (18S) A14064

Reference Link Ris
PubMed Search in Google Scholar
9 Cunningham D. et al . Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine. 2006; 355 11-20

Reference Link Ris
Crossref PubMed Search in Google Scholar
10 Cunningham D. et al . Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. JCO. 2006; 24 (18S) LBA4017

Reference Link Ris
PubMed Search in Google Scholar
11 Czito B G. et al . Preliminary results of a phase I study of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced or metastatic adenocarcinoma of the rectum. JCO. 2006; 24 (18S) A3543

Reference Link Ris
PubMed Search in Google Scholar
12 Di Fabio F. et al . 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study. JCO. 2006; 24 (18S) A4061

Reference Link Ris
PubMed Search in Google Scholar
13 Eckel F. et al . Chemotherapy in advanced biliary tract carcinoma (BTC): A comprehensive analysis. JCO. 2006; 24 (18S) A14036

Reference Link Ris
PubMed Search in Google Scholar
14 Feisthammel J. et al . Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinoma - a two-center phase II trial (GBFiri). JCO. 2006; 24 (18S) A14088

Reference Link Ris
PubMed Search in Google Scholar
15 Fiorica F. et al . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53 925-930

Reference Link Ris
Crossref PubMed Search in Google Scholar
16 Fuchs C. et al . A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). JCO. 2006; 24 (18S) A 3506

Reference Link Ris
PubMed Search in Google Scholar
17 Gerard J, Bonnetain F, Conroy T. et al . Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3 - 4 rectal cancers: results of the FFCD 9203 randomized trial. JCO. 2005; 23 A3504

Reference Link Ris
PubMed Search in Google Scholar
18 Greer S E. et al . Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005; 137 172-177

Reference Link Ris
Crossref PubMed Search in Google Scholar
19 Harder J. et al . Outpatient chemotherapy with gemcitabine and oxaliplatin in advanced biliary tract cancer; a phase II study. JCO. 2006; 24 (18S) A14006

Reference Link Ris
PubMed Search in Google Scholar
20 Heinemann V. et al . Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. JCO. 2006; 24 3946-3952

Reference Link Ris
Crossref PubMed Search in Google Scholar
21 Hochster H S. et al . Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. JCO. 2006; 24 (18S) A3510

Reference Link Ris
PubMed Search in Google Scholar
22 Hohler T. et al . ASCO-Update 2005 - Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005. Z Gastroenterol. 2005; 43 1253-1259

Reference Link Ris
Thieme Connect PubMed Search in Google Scholar
23 Igbal S. et al . A phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma. JCO. 2006; 24 (18S) A4134

Reference Link Ris
PubMed Search in Google Scholar
24 Kang Y. et al . Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. JCO. 2006; 24 (18S) LBA4018

Reference Link Ris
PubMed Search in Google Scholar
25 Kawamoto T. et al . Amplification of HER-2/neu (erb2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC). JCO. 2006; 24 (18S) A4011

Reference Link Ris
PubMed Search in Google Scholar
26 Kindler H L. et al . A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. JCO. 2006; 24 (18S) A4040

Reference Link Ris
PubMed Search in Google Scholar
27 Knox J J. et al . A phase II trial of oblimersen sodium (G3139) in combination with docorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5789. JCO. 2006; 24 (18S) A14072

Reference Link Ris
PubMed Search in Google Scholar
28 Ko A H. et al . A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa). JCO. 2006; 24 (18S) A4041

Reference Link Ris
PubMed Search in Google Scholar
29 Labianca R. et al . Alternating versus continuous „FOLFIRI” in advanced colorectal cancer (ACC): A randomized „GISCAD” trial. JCO. 2006; 24 (18S) A3505

Reference Link Ris
PubMed Search in Google Scholar
30 Lin C. et al . Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial. JCO. 2006; 24 (18S) A14129

Reference Link Ris
PubMed Search in Google Scholar
31 Machiels J P. et al . Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. JCO. 2006; 24 (18S) A3552

Reference Link Ris
PubMed Search in Google Scholar
32 Maindrault-Goebel F. et al . OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. JCO. 2006; 24 (18S) A3504

Reference Link Ris
PubMed Search in Google Scholar
33 Marijnen C. et al . Long term results, toxicity and quality of life in the TME trial. ASCO Gastrointestinal Cancers Symposium. 2006; A166

Reference Link Ris
PubMed Search in Google Scholar
34 Moehler M. et al . Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study. JCO. 2006; 24 (18S) A4032

Reference Link Ris
PubMed Search in Google Scholar
35 Moore M J. et al . Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). JCO. 2005; 23 A1

Reference Link Ris
PubMed Search in Google Scholar
36 Morinaga S. et al . Expression of Epidermal growth factor receptor (EGFR) associates with proliferation, apoptosis, and histologically aggressive features in hepatocellular carcinoma. JCO. 2006; 24 (18S) A14039

Reference Link Ris
PubMed Search in Google Scholar
37 Nehls O. et al . A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas: The final results. JCO. 2006; 24 (18S) A4136

Reference Link Ris
PubMed Search in Google Scholar
38 Neuhaus P, Oettle H, Post S. et al . A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. JCO. 2005; 23 A4013

Reference Link Ris
PubMed Search in Google Scholar
39 Nordlinger P. et al . Complete radiological response of colorectal liver metastases (LM) chemotherapy: Does it mean cure?. JCO. 2006; 24 (18S) A3501

Reference Link Ris
PubMed Search in Google Scholar
40 O’Dwyer P J. et al . Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203. JCO. 2006; 24 (18S) A4143

Reference Link Ris
PubMed Search in Google Scholar
41 Poplin E. et al . Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). JCO. 2006; 24 (18S) LBA4004

Reference Link Ris
PubMed Search in Google Scholar
42 Qin SK. et al . Preliminary results of a phase II trial of FOLFOX4 regimen in Chinese patients with unresectable primary liver cancer. JCO. 2006; 24 (18S) A14065

Reference Link Ris
PubMed Search in Google Scholar
43 Quirke P. et al . Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. JCO. 2006; 24 (18S) A3512

Reference Link Ris
PubMed Search in Google Scholar
44 Ramanathan R K. et al . Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. JCO. 2006; 24 (18S) A4010

Reference Link Ris
PubMed Search in Google Scholar
45 Regine W F. et al . RTOG 9704a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. JCO. 2006; 24 (18S) A4007

Reference Link Ris
PubMed Search in Google Scholar
46 Richards D A. et al . Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. JCO. 2006; 24 (18S) A4071

Reference Link Ris
PubMed Search in Google Scholar
47 Rizk N P. et al . Impact of pre-operative chemoradiotherapy on post-esophagectomy morbidity and mortality. JCO. 2006; 24 (18S) A4025

Reference Link Ris
PubMed Search in Google Scholar
48 Roedel K. et al . Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer. ASCO Gastrointestinal Cancer Symposium. 2006; A349

Reference Link Ris
PubMed Search in Google Scholar
49 Sauer R. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351 1731-1740

Reference Link Ris
Crossref PubMed Search in Google Scholar
50 Schwartz J D. et al . Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. JCO. 2006; 24 (18S) A4144

Reference Link Ris
PubMed Search in Google Scholar
51 Sebag-Montefiore D. et al . Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. JCO. 2006; 24 (18S) A3511

Reference Link Ris
PubMed Search in Google Scholar
52 Shah M A. et al . Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). JCO. 2006; 24 (18S) A4020

Reference Link Ris
PubMed Search in Google Scholar
53 Sharma A. et al . Gemcitabine and oxaliplatin (Gemox) in advanced/unresectable gall bladder cancer: A phase II study. JCO. 2006; 24 (18S) A14027

Reference Link Ris
PubMed Search in Google Scholar
54 Siegel A B. et al . Current treatments, determinants of use, and survival for patients with hepatoma in the United States from 1998 - 2002. JCO. 2006; 24 (18S) A4138

Reference Link Ris
PubMed Search in Google Scholar
55 Stahl M, Stuschke M, Lehmann N. et al . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. JCO. 2005; 23 2310-2317

Reference Link Ris
Crossref PubMed Search in Google Scholar
56 Tebbutt N. et al . Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. JCO. 2006; 24 (18S) A4067

Reference Link Ris
PubMed Search in Google Scholar
57 Tepper J E. et al . Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. JCO. 2006; 24 A 4012

Reference Link Ris
PubMed Search in Google Scholar
58 Urschel J D. et al . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185 538-543

Reference Link Ris
Crossref PubMed Search in Google Scholar
59 Venook A. et al . Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80 203 preliminary results. JCO. 2006; 24 (18S) A3509

Reference Link Ris
PubMed Search in Google Scholar
60 Willett C G. et al . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10 145-147

Reference Link Ris
Crossref PubMed Search in Google Scholar
61 Yu S C. et al . Transarterial ethanol ablation of unresectable hepatocellular carcinoma with lipiodol-ethanol mixture (LEM): A phase II study. JCO. 2006; 24 (18S) A14054

Reference Link Ris
PubMed Search in Google Scholar
62 Yu J. et al . A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. JCO. 2006; 24 (18S) A4013

Reference Link Ris
PubMed Search in Google Scholar
63 Zhu A X. et al . Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. JCO. 2006; 24 (18S) A14096

Reference Link Ris
PubMed Search in Google Scholar

1 für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS.

Thomas Seufferlein

Klinik für Innere Medizin I, Universitätsklinikum Ulm

Robert-Koch-Str. 8

89081 Ulm

Email: thomas.seufferlein@uniklinik-ulm.de

Related Journals

Related Books